帕妥珠单抗与曲妥珠单抗新辅助双靶向治疗在HER2阳性乳腺癌临床治疗中的应用研究

Application of neoadjuvant double-targeted therapy of pertuzumab and trastuzumab in the clinical treatment of HER2 positive breast cancer

目的探究帕妥珠单抗与曲妥珠单抗新辅助双靶向治疗在人表皮生长因子受体2(HER2)阳性乳腺癌临床治疗中的应用效果。方法选取我院2021年1月~2023年12月收治的102例HER2阳性乳腺癌患者为研究对象,按照随机数字表法分为研究组与对照组,各51例。两组均行新辅助化疗,在此基础上对照组接受曲妥珠单抗治疗,研究组接受帕妥珠单抗与曲妥珠单抗双靶向治疗。比较两组疗效、三叶因子1(TFF1)、人类泛素偶联酶E2C(UBE2C)、免疫指标、生活质量及不良反应。结果研究组客观缓解率高于对照组(86.27%vs.66.67%,P<0.05)。治疗后,研究组TFF1、UBE2C水平较治疗前及对照组低(P<0.05)。治疗后,研究组CD_(3)^(+)、CD_(4)^(+)T细胞及CD_(4)^(+)/CD_(8)^(+)水平低于治疗前,高于对照组,CD_(8)^(+)T细胞水平高于治疗前,低于对照组(P<0.05)。治疗后,研究组生活质量各维度评分比治疗前及对照组高(P<0.05)。两组各不良反应发生率相比,差异无统计学意义(P>0.05)。结论帕妥珠单抗与曲妥珠单抗新辅助双靶向治疗在HER2阳性乳腺癌临床治疗中的应用效果确切,可明显减小对机体免疫功能的影响,且安全性较高。

Objective To investigate the effect of neoadjuvant double-targeted therapy of pertuzumab and trastuzumab in the clinical treatment of human epidermal growth factor receptor 2(HER2)positive breast cancer.Methods 102 patients with HER2 positive breast cancer admitted to our hospital from Jan 2021 to Dec 2023 were divided into the control group and the study group according to random number table method.Both groups received neoadjuvant chemotherapy,and on this basis,the control group(n=51)received treatment with trastuzumab,the study group(n=51)received double-targeted therapy with pertuzumab and trastuzumab.The efficacy,TFF1,human ubiquitin conjugating enzyme E2C(UBE2C),immune indexes,quality of life and adverse reactions were compared between the two groups.Results The objective remission rate of the study group was higher than that of the control group(86.27%vs.66.67%,P<0.05).After treatment,TFF1 and UBE2C in the study group were lower than those before treatment and in the control group(P<0.05).After treatment,the levels of CD_(3)^(+),CD_(4)^(+)T lymphocytes and CD_(4)^(+)/CD_(8)^(+)in the study group were lower than before treatment,but CD_(8)^(+)T limphocytes was higher than before treatment,and the levels of CD_(3)^(+),CD_(4)^(+)T lymphocytes and CD_(4)^(+)/CD_(8)^(+)were higher than that of the control group,and the level CD_(8)^(+)T lymphocytes was lower than that of the control group(P<0.05).After treatment,the scores of quality of life in the study group were higher than those before treatment and in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The neoadjuvant double-targeted therapy of pertuzumab and trastuzumab is effective in the clinical treatment of HER2 positive breast cancer,With high safety,it can significantly reduce the expression of oncogenes in patients and reduce the influence on the immune function of the body.